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that is predictive of the fibrotic potential of MWCNTs. 
While fibrosis takes weeks or months to develop in vivo, 
an in vitro test system may more rapidly predict fibro-
genic potential by monitoring pro-fibrotic mediators (e.g., 
cytokines and growth factors). Therefore, the workshop 
discussions focused on the necessary specifications related 
to the development and evaluation of such an in vitro sys-
tem. Recommendations were made for designing a system 
using lung-relevant cells co-cultured at the air–liquid inter-
face to assess the pro-fibrogenic potential of aerosolized 
MWCNTs, while considering human-relevant dosimetry 
and NM life cycle transformations. The workshop discus-
sions provided the fundamental design components of an 
air–liquid interface in vitro test system that will be subse-
quently expanded to the development of an alternative test-
ing strategy to predict pulmonary toxicity and to generate 
data that will enable effective risk assessment of NMs.
Abstract The increasing use of multi-walled carbon 
nanotubes (MWCNTs) in consumer products and their 
potential to induce adverse lung effects following inhala-
tion has lead to much interest in better understanding the 
hazard associated with these nanomaterials (NMs). While 
the current regulatory requirement for substances of con-
cern, such as MWCNTs, in many jurisdictions is a 90-day 
rodent inhalation test, the monetary, ethical, and scien-
tific concerns associated with this test led an international 
expert group to convene in Washington, DC, USA, to dis-
cuss alternative approaches to evaluate the inhalation tox-
icity of MWCNTs. Pulmonary fibrosis was identified as a 
key adverse outcome linked to MWCNT exposure, and rec-
ommendations were made on the design of an in vitro assay 
Disclaimer: The views expressed in this publication are those of 
the authors and do not necessarily represent the views, policies, 
or official positions of the NIEHS, NTP, US EPA, or any Federal 
agency. Mention of trade names or commercial products does not 
constitute endorsement or recommendation for use.
 * Amy J. Clippinger 
 AmyJC@PISCLtd.org.uk
1 PETA International Science Consortium Ltd., London, UK
2 University of Pisa, Pisa, Italy
3 Contractor Supporting the National Toxicology Program 
Interagency Center for the Evaluation of Alternative 
Toxicological Methods, Integrated Laboratory Systems, Inc., 
Research Triangle Park, NC, USA
4 North Carolina State University, Raleigh, NC, USA
5 NTP Interagency Center for the Evaluation of Alternative 
Toxicological Methods, Raleigh, NC, USA
6 West Virginia University, Morgantown, WV, USA
7 BASF Corporation, Florham Park, NJ, USA
8 Environmental and Radiation Health Sciences Directorate, 
Health Canada, Ottawa, ON, Canada
9 The Dow Chemical Company, Midland, MI, USA
10 U.S. Environmental Protection Agency, Research Triangle 
Park, NC, USA
11 Evonik Industries AG, Hanau-Wolfgang, Germany
12 Adolphe Merkle Institute, University of Fribourg, Fribourg, 
Switzerland
13 Department of Environmental Science, Baylor University, 
Waco, TX, USA
14 nanoRisk Analytics, LLC, Washington, MD, USA
15 Heriot-Watt University, Edinburgh, UK
1770 Arch Toxicol (2016) 90:1769–1783
1 3
Keywords Inhalation toxicity · Multi-walled carbon 
nanotubes · MWCNTs · In vitro testing strategies · 
Regulatory risk assessment · Pulmonary fibrosis
Abbreviations
ALI  Air–liquid interface
AOP  Adverse outcome pathway
APS  Aerodynamic particle sizer
ARA  Applied Research Associates, Inc
ATCC  American Type Culture Collection
BET  Brunauer, Emmett, and Teller
BPR  Biocidal Products Regulation
BVD  Bivariate distribution
CCL-2  Chemokine (C–C motif) ligand 2
CEPA  Canadian Environmental Protection Act
CLP  Classification, Labelling and Packaging
CNT  Carbon nanotubes
COPD  Chronic obstructive pulmonary disease
DSMZ  German Collection of Microorganisms and 
Cell Cultures
ELISA  Enzyme-linked immunosorbent assay
EPA  Environmental Protection Agency
ESAC  ECVAM Scientific Advisory Committee
FACS  Fluorescence-activated cell sorting
ICP-MS  Inductively coupled plasma mass spectrometry
ISDD  In vitro sedimentation, diffusion, and 
dosimetry
IVIVE  In vitro to in vivo extrapolation
JRC  Joint Research Centre
LDH  Lactate dehydrogenase
MALI  Membrane air–liquid interface
MMAD  Mass median aerodynamic diameter
MOUDI  Micro-orifice uniform deposit impactor
MPPD  Multiple-path particle dosimetry
MWCNT  Multi-walled carbon nanotube
NAAQS  National Ambient Air Quality Standards
NGO  Non-governmental organization
NIOSH  National Institute for Occupational Safety and 
Health
NM  Nanomaterial
NSNR  New Substances Notification Regulations
OECD  Organisation for Economic Co-operation and 
Development
OPN  Osteopontin
PDGF  Platelet-derived growth factor
PMN  Premanufacture notice
QCM  Quartz crystal microbalance
RCF  Refractory ceramic fiber
REACH  Registration, Evaluation, Authorisation and 
Restriction of Chemicals
SEM  Scanning electron microscope
SMPS  Scanning mobility particle sizer
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Introduction
Inhalation is considered an important route of entry into 
the human body for aerosolized nanomaterials (NMs) 
released into the environment (during production, process-
ing, intended usage, or disposal of products). Research 
into the potential hazards of these materials has therefore 
often focused on effects on the respiratory tract as a target 
tissue. Traditional in vivo inhalation toxicity tests require 
large numbers of animals, specialized facilities, and exper-
tise, and are resource-intensive with respect to both time 
and cost. Concerns related to the use of animals, cost, and 
time as well as the technical difficulty and weak predic-
tive ability of the 90-day rodent inhalation test for humans 
have motivated interest in developing in vitro lung cell-
based methods. As the prevalence and diversity (different 
functionalization or physical–chemical properties) of NMs 
in commerce continues to grow, so does the need for effi-
cient and accurate, human-relevant test methods to assess 
the potential hazards associated with NMs in a timely 
manner.
With this in mind, in February 2015, the PETA Inter-
national Science Consortium Ltd. co-organized with the 
US National Toxicology Program Interagency Center 
for the Evaluation of Alternative Toxicological Meth-
ods a workshop that was attended by international rep-
resentatives from industry, government, academia, and 
non-governmental organizations with expertise in in vivo 
and in vitro lung systems, respiratory toxicology, inhala-
tion particle dosimetry, nanotoxicology, and hazard and 
human health risk analysis. The goal of the workshop was 
to review the state of the science and determine the tech-
nical needs to develop an in vitro system that will reduce 
and eventually replace the use of animals for evaluating 
the potential inhalation toxicity of NMs in a regulatory 
setting. The workshop discussion focused specifically on 
the development and preliminary assessment of the rel-
evance and reliability of an in vitro test system to predict 
the development of pulmonary fibrosis by assessing pro-
fibrogenic markers in lung cells cultured at the air–liquid 
interface (ALI) following exposure to aerosolized NMs, 
such as multi-walled carbon nanotubes (MWCNTs). This 
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report provides an overview of the discussions on the 
design of an in vitro system for the prediction of pulmo-
nary fibrosis.
Regulatory landscape
The increasing use of NMs in consumer-based products 
warrants a thorough evaluation of their eco- and bio-
logical impacts. The general consensus among various 
international jurisdictions is that the existing regulatory 
frameworks are appropriate for the assessment of NMs; 
however, some adaptations have been made or may be 
required to consider “nano”-specific properties (OECD 
2012a; Scott-Fordsmand et al. 2014; Stone et al. 2014). At 
this time, the US Environmental Protection Agency (US 
EPA) Toxic Substances Control Act (TSCA) addresses 
one of the highest numbers of NM-containing products 
of any authority (more than 160 NMs reviewed to date) 
(2015) and, the majority of US EPA Premanufacture 
notices (PMNs) for NMs are for MWCNTs [for details 
on US EPA’s New Chemicals Program, see (Godwin et al. 
2015)]. The information pertaining to the assessment of 
NMs by regulatory agencies in the USA, European Union 
(EU), and Canada is described in Table 1. A description 
of exposure assessment tools for NMs is available online 
(Hanes et al. 2000).
While different jurisdictions vary in regulatory require-
ments and working definitions for NMs, all require expo-
sure and toxicity data for risk assessment and management 
purposes. The growing number of NMs in consumer prod-
ucts requires ways to prioritize them for assessment in an 
efficient and cost-effective manner. Factors, such as pro-
duction volumes, extent of use in consumer products, and 
evident bio- or ecological toxicity (based on existing data), 
can aid in the prioritization process.
Design of an integrated approach to testing 
and assessment
Often for aerosolized materials, human risk analysis is 
based upon 90-day inhalation studies using rodents [e.g., 
Organisation for Economic Co-operation and Development 
(OECD) test guideline 413 (OECD 2009)]. While these 
longer-term rodent tests have been historically used for risk 
assessment purposes, they do not perfectly predict the 
human response. There are clear anatomical, physiological, 
and molecular differences between humans and rodents 
that impact the deposition, transport, and potential toxicity 
of inhaled particles. Such differences include the dimen-
sions of the airway architecture and the impact of increased 
nasal deposition in obligate nose-breathing species, such as Ta
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rats, compared to humans. Additionally, the 90-day OECD 
inhalation test guideline does not provide information 
about the activation of complex signaling pathways.1
In vitro test methods provide the opportunity to investi-
gate such mechanisms in detail as well as the potential to 
be scaled for higher throughput (Nel et al. 2012; Godwin 
et al. 2015), thus addressing the need to rapidly test large 
numbers of NMs. However, a single assay is unlikely to be 
able to accommodate the assessment of the complexity of 
the full respiratory tissue response to NMs or other sub-
stances; instead, a battery of complimentary tests will be 
required.
In addition to in vitro assays, a non-animal approach 
(one that does not use live animals) relevant for assessing 
inhalation hazard of NMs may include the use of exist-
ing data (in vivo or in vitro), grouping (i.e., categorization 
based on similar attributes or features of interest), and read-
across [i.e., predicting the toxicity of one substance based 
on data from other substance(s)] (Oomen et al. 2014), and 
in silico (computational) models (Winkler et al. 2012). 
In vitro testing representing the lung can range from simple 
cell-free biochemical assays (Zielinski et al. 1999; Mud-
way et al. 2004), to submerged cell monoculture systems 
(Foucaud et al. 2007; Rotoli et al. 2008; Foucaud et al. 
2010; McCarthy et al. 2011; Banga et al. 2012; Bhattacha-
rya et al. 2013; Nymark et al. 2013; Gliga et al. 2014), 
through to exposing three-dimensional (3D) cultures grown 
at the air–liquid interface (ALI) which contain a fully dif-
ferentiated epithelium with more than one cell type and a 
morphology similar to that observed in vivo (Klein et al. 
2013; Herzog et al. 2014). Each test system can be used 
to evaluate biomarkers (e.g., antioxidant depletion or pro-
inflammatory cytokine expression) linked to pulmonary 
pathologies (Fig. 1). To be useful for regulatory risk assess-
ment, these biomarkers should include those that address 
both early and late events in pathologies and diseases, such 
as fibrosis, chronic obstructive pulmonary disease (COPD), 
emphysema, and asthma (both sensitization/induction and 
elicitation/exacerbation. Each of the methods involved in a 
non-animal approach has advantages and limitations which 
are important to understand when used for human risk 
assessment. This workshop report focuses on identifying 
1 OECD test guideline 413 states that it was designed to character-
ize subchronic toxicity by the inhalation route and to provide data for 
quantitative inhalation risk assessment. In this test, 10 male and 10 
female rodents are exposed 6 h per day, 5 or 7 days per week, during 
a 90-day period to at least three concentration levels, filtered air (neg-
ative control), and/or the vehicle (vehicle control). The results of the 
study include hematology, clinical chemistry, ophthalmology, gross 
pathology, organ weights, and histopathology. For more details, see 
OECD (2009). Test No. 413: Subchronic Inhalation Toxicity: 90-day 
Study, OECD Publishing.
and recommending the key features that should be consid-
ered when developing and evaluating an ALI system for 
inhalation toxicology. As for other non-animal approaches, 
development of an ALI system requires benchmark (con-
trol) toxic and non-hazardous substances or particles for 
which considerable human and/or animal data are already 
available in order to allow comparison of results and to aid 
in their interpretation. As experience with, and confidence 
in, the test system increases, its use could be expanded to 
the toxicity ranking (e.g., fibrotic potential) of substances 
or particles for use in regulatory assessment.
Fibrosis induction by MWCNTs: an end point 
relevant to assessing NM hazard
Fibrosis, in general, is a deregulated wound-healing pro-
cess and involves uncontrolled deposition of extracellular 
matrix (e.g., collagen) leading to the formation of scar tis-
sue. In the lower respiratory tract, excessive fibrosis (e.g., 
after high dose or prolonged exposure to a damaging sub-
stance) results in a loss of tissue elasticity and reduced lung 
function (Palecanda and Kobzik 2001; Oberdorster et al. 
2005; OECD 2012b). Fibrosis is of key regulatory impor-
tance because it is an important pathological consequence, 
which in itself is debilitating, but also is often associated 
with other pathologies, such as particle-induced lung can-
cers, since both are driven in part by chronic inflammation.
Among the different types of NMs that are commer-
cially available today, carbon nanotubes (CNTs), especially 
MWCNTs, stand out as model NMs of research interest for 
inhalation toxicity. MWCNTs are increasingly synthesized 
and widely used in consumer products, which has lead to 
Existing information (including human, animal, 
in silico, or in vitro data) 
In Silico modeling In vitro methods
Weight of evidence
Human safety assessment
G
ro
up
in
g
Fig. 1  Integrated non-animal approach to assess the inhalation tox-
icity of aerosolized nanomaterials. This approach should include the 
use of existing information, grouping (e.g., categorization of NMs 
based on exposure, mode of action, or physicochemical properties, 
among other factors), in silico modeling, and the use of in vitro meth-
ods of varying complexity
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much research on these materials (Vance et al. 2015). The 
high aspect ratio (i.e., long and narrow fiber-like shape) of 
CNTs together with their potential for persistence in the 
lower respiratory tract has raised the concern that long-term 
exposure to CNTs via inhalation may also lead to patholo-
gies analogous to those observed with other fibrous parti-
cles (OECD 2009). In fact, pulmonary fibrosis is the most 
extensively reported adverse outcome for MWCNTs in 
existing in vivo studies. Further, a chronic inhalation study 
has linked MWCNTs (Mitsui 7s) with fibrosis in rodents 
(Fukushima et al., in preparation). Studies have shown that 
the potential for inhaled MWCNTs to induce fibrosis is 
influenced by their physicochemical properties (Ma-Hock 
et al. 2009; Mishra et al. 2012; Sargent et al. 2014; Francis 
et al. 2015). Fibrosis is therefore an important and relevant 
end point to consider for the risk assessment of MWCNT.
A range of in vitro methods have been published that 
assess the pulmonary toxicity of MWCNTs. A num-
ber of these in vitro studies have been directly compared 
with studies in animals. For example, Taylor et al. (2014) 
have shown that coating MWCNTs with aluminum oxide 
decreased the production of certain pro-fibrotic markers 
(osteopontin, interleukin-6, and tumor necrosis factor-α) 
in THP-1 human monocytic cells in vitro, which correlated 
with reduced fibrosis observed in mice after 28 days of 
exposure via oropharyngeal aspiration. Vietti et al. (2013) 
demonstrated a dose-dependent stimulation of fibroblast 
proliferation in vitro following exposure to longer MWC-
NTs (0.7–3 and 0.7–4 µm for NM 400 (Nanocyl, Bel-
gium) and NM 402 (Arkema, France), respectively), but no 
induction of fibroblast proliferation following exposure to 
shorter MWCNTs (0.14–0.5 and 0.7 µm for crushed forms 
of NM 400 and NM 402, respectively) as measured by cell 
counting, WST-1 assay, and propidium iodide staining. The 
fibroblast proliferation observed in vitro reflects the results 
observed in mice exposed to MWCNTs via oropharyngeal 
aspiration (increased fibroblast proliferation and colla-
gen accumulation observed 60 days post-exposure) (Vietti 
et al. 2013). Mishra et al. reported increased TGF-β secre-
tion (as determined by ELISA and Western blotting) from 
human lung epithelial cells (BEAS-2B cells) and human 
lung fibroblasts (CRL-1490 cells) as well as increased 
proliferation (as determined by the WST-1 assay) and col-
lagen production (as measured by the Sircol™ Collagen 
Assay and Western blotting) in human lung fibroblasts 
(CRL-1490 cells) after treatment with Mitsui 7 MWCNTs 
(Godwin et al. 2015; Mishra et al. 2015). The Sircol™ Col-
lagen Assay has been used in situ and in vitro for assess-
ing collagen production, as a quantitative marker of fibrosis 
induction (Wang et al. 2011). Thus, in addition to providing 
evidence that MWCNTs may cause fibrosis, these studies 
provide evidence that in vitro models and a range of bio-
logical markers can be used in vitro to predict the fibrotic 
response. These data therefore provide a starting point for 
identifying useful biomarkers to assess pulmonary fibro-
genic potential in vitro, which can be combined with infor-
mation from other fibrogenic materials such as silica and 
asbestos, in order to generate a more comprehensive suite 
of pro-fibrotic biomarkers. Accordingly, focused efforts are 
required to further develop this existing knowledge using 
in vitro methods to assess the fibrogenic potential of parti-
cles such as MWCNTs.
An adverse outcome pathway for pulmonary 
fibrosis
A decade of nanotoxicology research has revealed a range 
of mechanisms by which NMs can induce toxicity; how-
ever, integration of this knowledge to support regula-
tory decision making has been a challenge (Fedan et al. 
2014; Haniu et al. 2014; Hussain et al. 2014; Kim et al. 
2014; Dong et al. 2015). The development of well-defined 
adverse outcome pathways (AOPs)—a conceptual frame-
work that links a molecular initiating event to an adverse 
outcome at a biological level of organization relevant to 
risk assessment (Ankley et al. 2010)—can help in (1) sys-
tematically organizing existing scientific information con-
cerning NM-induced toxicity; (2) identifying knowledge 
gaps; (3) informing the design of relevant in vitro predic-
tive assays and testing strategies to help inform risk assess-
ment; and (4) guiding future research priorities. AOPs are 
gaining acceptance as a way to assist in regulatory deci-
sions which are based on mechanistic understandings and 
may reduce reliance on in vivo data (with quantitative 
dosimetry issues considered separately as part of an inte-
grated approach).For instance, Labib et al. (2016) demon-
strated the use of existing transcriptomics data to construct 
a hypothetical AOP that shows the sequential develop-
ment of fibrotic lesions in the lungs after initial exposure 
to MWCNTs. Such a transcriptomics/AOP approach may 
be applied toward hazard ranking of MWCNTs based on 
their potential to cause fibrosis and aid in regulatory deci-
sion making. There are a large number of AOPs currently 
under review within the OECD.
An AOP with a specific molecular initiating event and 
key events involved in the process of pulmonary fibrosis 
may inform the selection of in vitro end points and assay 
design (Fig. 2). Key events to assess can be grouped into 
low-priority and high-priority categories based on their rel-
evance to the adverse fibrotic outcome and the availability 
of information and applicable techniques. The lower pri-
ority events include initial (pro-) inflammatory signaling 
(Fig. 2, step 2) assessed by multiplex ELISAs, the forma-
tion of reactive oxygen species (ROS; Fig. 2, step 3b), and 
cellular toxicity and death (Fig. 2, step 3c), which could 
1774 Arch Toxicol (2016) 90:1769–1783
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be determined by assessing ROS generation, epithelial 
cell apoptosis, and the analysis of mRNA and protein lev-
els of platelet-derived growth factor (PDGF), osteopontin 
(OPN), tenascin-C (TN-C), and chemokine (C–C motif) 
ligand 2 (CCL-2). The higher priority key events include 
fibroblast and myofibroblast proliferation (Fig. 2, step 7), 
resulting in excessive collagen synthesis and extracellular 
matrix deposition (Fig. 2, step 8). Thus, AOPs can help 
identify suitable key events to serve as indicators of fibrotic 
potential and specific biomarkers to assess using a targeted 
omics approach. More specifically, addressing the high-
priority key events outlined above would include assessing 
total collagen deposition (e.g., via Sircol™ assay), fibro-
blast proliferation (via FACS analysis, cell counting under 
microscope, WST-1 assay, or propidium iodide staining), 
TGF-β expression (via ELISA or Western blotting for pro-
tein levels, or via RT-PCR or Northern blotting for mRNA 
levels), and overall cytotoxicity (via LDH assay). Integral 
to the proposed AOP is the bio-persistence of MWCNTs, 
which when retained in the lung tissue for a long dura-
tion after exposure, will contribute to ongoing tissue injury 
(Fig. 2, step 4) and continued stimulation of wound-healing 
processes including the secretion of inflammatory media-
tors and growth factors. This interaction of MWCNTs with 
lung tissue and the resultant inflammatory response can be 
qualitatively assessed by several microscopic methods.
MWCNTs of interest
Ideally, a minimum of two different MWCNTs should be 
used to develop and test the in vitro system, one that has 
been demonstrated to be highly pro-fibrogenic and one that 
induces less fibrosis in in vivo and in vitro studies. Con-
sequently, Mitsui-7s, which have been shown to be highly 
toxic, and Nanocyl 7000 MWCNTs [NM 400 from the 
European Commission Joint Research Centre (JRC)], 
which have been shown to be less toxic, would provide a 
good comparison (van Berlo et al. 2014). Importantly, both 
materials have been well characterized and tested for their 
ability to induce fibrosis in vitro and in vivo (via instilla-
tion, pharyngeal aspiration, or nose-only inhalation expo-
sure and assessed up to 90 days post-exposure), and it was 
demonstrated that the Nanocyl 7000 MWCNTs are fibro-
genic but less so than the Mitsui-7s (Ma-Hock et al. 2009; 
Vietti et al. 2013; van Berlo et al. 2014; Poulsen et al. 
2015). In addition, asbestos (e.g., long fiber amosite or cro-
cidolite), which has been shown to induce lung fibrosis in 
rodents and in humans, could serve as a positive control. A 
secondary positive control option is crystalline silica (e.g., 
MIN-U-SIL-5® or DQ12) as it is another relatively insol-
uble inhaled particle. Negative controls could include a 
highly soluble refractory ceramic fiber (RCF) (e.g., RCF1) 
or carbon black (e.g., Printex® 90) (Mast et al. 1994; 
Bellmann et al. 2001; Sanchez et al. 2011; Hussain et al. 
2014) in addition to NM-free air (untreated control for ALI 
exposures).
Suggestions for advanced in vitro lung models 
in nanotoxicology research
There are numerous in vitro lung models that can be used 
to study the cellular interplay and cellular responses fol-
lowing NM exposure (Jud et al. 2013). They range from 
simple monocultures (Lehr 2002; Steimer et al. 2005) to 
Organ Response Organism Response
1. 
Physical interaction of 
substances with 
biological milieu - cell 
membrane, lung 
surfactant, proteins, 
and other molecules
2.
Induction of 
secretion of 
inflammator
y cytokines 
3a.
Induction of 
acute phase 
response;
propagation 
of 
inflammator
y response
5. 
Tissue 
injury
6
TH2/M2 
response, 
secretion and 
activation of 
interleukins 
and growth 
factors
7. 
Fibroblast / 
myofibroblast 
proliferation
8. 
Extracellular 
matrix 
deposition
9. 
Fibrosis
4. 
Retention of or 
repeated 
exposure to 
foreign material 
leading to 
continuous 
inflammation
Molecular 
Initiating Event Cellular Response
Pulmonary injury leading to fibrosis
3b.
Reactive
oxygen 
species
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Fig. 2  Putative adverse outcome pathway (AOP) for pulmonary fibrosis. The schematic shows the putative molecular initiating event, key 
events, and adverse outcome of an AOP presented during the workshop
1775Arch Toxicol (2016) 90:1769–1783 
1 3
highly sophisticated 3D co-culture models (Rothen-Rut-
ishauser et al. 2005; Rothen-Rutishauser et al. 2008; Huh 
et al. 2010; Klein et al. 2012; Bove et al. 2013; Herzog 
et al. 2013; Li et al. 2013; Herzog et al. 2014; Chortarea 
et al. 2015), which represent a more realistic physiological 
situation (Carterson et al. 2005). While simpler cell cul-
ture systems can be useful, with the advantages of being 
potentially cheaper and more amenable to high-throughput 
assay design, there have been significant advancements in 
the development of well-characterized 3D, multi-cellular 
tissue models that allow for the investigation of cellular 
interplay between different cell types following exposure to 
NMs. Furthermore, exposing lung cells cultured at the ALI 
to aerosolized NMs allows for even more human-relevant 
exposure conditions.
A number of factors influence the successful use of 
advanced in vitro models, some of which are outlined here. 
For any cell culture work, it is critical that details on cul-
ture conditions (e.g., dishes, medium, and supplements) are 
reported, since cell lines can behave differently depend-
ing on these variables (Hartung et al. 2002; Coecke et al. 
2005). Use of original cell lines obtained from recognized 
organizations, such as the American Type Culture Collec-
tion (ATCC), European Collection of Authenticated Cell 
Cultures (ECACC), or the German Collection of Micro-
organisms and Cell Cultures (DSMZ), helps to ensure the 
authenticity of the cells and to ensure that they have been 
handled using routine procedures with relatively low pas-
sage numbers. Many studies suggest that the use of early 
passage cells is preferable since later passages of some 
cells cultures can lose their phenotype or become senes-
cent. Monitoring cellular morphology, structure, and func-
tion [e.g., by measuring tight junctions via transepithelial 
electrical resistance (TEER)] as well as the expression 
of cell type-specific surface proteins should be used over 
time to identify whether cells lose their specific phenotype. 
The use of animal-derived media supplements, such as 
fetal bovine serum, can pose ethical as well as reproduc-
ibility issues (Palecanda and Kobzik 2001; Mishra et al. 
2015). Therefore, the use of chemically defined, serum-free 
medium was recommended, which is also in accordance 
with the ECVAM Scientific Advisory Committee (ESAC) 
statement promoting non-animal alternatives to fetal calf 
serum (ESAC 2008). 3D models can contain a range of dif-
ferent cell types in different orientations and numbers, and 
to obtain a model best reflecting a normal or diseased state 
tissue physiology, organ-relevant ratios of cell types should 
be used and organized in a structure that reflects the tissue 
of interest.
Using technologies that are currently available and 
accessible across laboratories, we recommend an approach 
which co-cultures fibroblasts on the basal surface of Tran-
swell® or other cell culture inserts with macrophages and 
alveolar epithelial cells on the apical surface in order to 
generate an in vitro system to predict fibrosis when exposed 
to aerosolized NMs at the ALI (Fig. 3). Other co-culture 
systems have been described which included endothelial 
cells, dendritic cells, and mast cells (Hermanns et al. 2004; 
Alfaro-Moreno et al. 2008; Rothen-Rutishauser et al. 2008; 
Klein et al. 2013); however, because increasing the num-
ber of cell types makes it more difficult to maintain optimal 
culture conditions, only the cells which are central for a 
pathological process should be prioritized. In the case of a 
fibrosis model, these are epithelial cells, macrophages, and 
fibroblasts.
The use of primary cells is optimal, recognizing that 
the use of primary cells may lead to increased interlabo-
ratory variability. The use of human cells is ideal because 
the regulatory need is to predict the human, rather than the 
rodent, response. The use of human cells is also in line with 
a twenty-first century vision of toxicology (NRC 2007). 
However, when validating against the historical 90-day 
Fig. 3  Experimental design 
of a lung co-culture system to 
study the fibrotic potential of 
substances. Schematic shows 
macrophages and alveolar 
epithelial cells cultured on a cell 
culture insert that is exposed 
at the air–liquid interface to 
aerosolized MWCNTs, while 
fibroblasts are cultured on the 
basal surface of the membrane
CNTs
Fibroblasts
Alveolar cells 
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Medium
Insert
Tissue 
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Airflow
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rodent inhalation studies, it is unknown whether rodent 
cells may show greater concordance. There was discussion 
of using the commercially available reconstructed human 
lower respiratory tract tissue model, EpiAlveolar™ (Mat-
Tek Corp., Ashland, MA) (Jackson et al. 2013); however, 
insufficient published data are currently available to fully 
understand its applicability to these studies.
In a static ALI system, factors secreted from the alveolar 
cells and macrophages are small enough to pass through the 
pores of the cell culture inserts, but the MWCNT agglom-
erates may be too large to do so. Thus, this in vitro test sys-
tem is not ideal for studying the translocation of MWCNTs 
to the fibroblasts cultured on the basal side. However, the 
effect of MWCNTs on fibroblasts can be assessed by con-
ducting parallel testing in a simple submerged cell culture 
system.
In vitro air–liquid interface exposure systems
In order to more closely mimic the conditions of the human 
lung, to maximize the human relevance of in vitro testing, 
and to simplify the dose metric calculations, the exposure 
of cells cultured at the ALI to aerosolized materials is of 
significant research interest. The typical setup of an expo-
sure system built to deliver NMs to ALI cultures involves 
three components: (1) an aerosol generator, (2) connec-
tions and peripherals, and (3) the exposure chamber. The 
generator creates the aerosol by a technology appropriate to 
the physical state of the NM. Dust feeding, brush feeding, 
turntable, acoustic, cyclone sieve, fluidized bed, and string 
technology have all been used to generate aerosols from 
powders/dusts, while electrospray and nebulizing genera-
tors have been used to aerosolize particles in liquid droplets 
(Cheng 1986; Moss et al. 1994; Jarabek et al. 2005; Tee-
guarden et al. 2007; Bouwmeester et al. 2011). The con-
nections and peripherals are the intermediate devices and 
tubing or channels used to transport, dilute, characterize, 
and condition the aerosol prior to deposition. The exposure 
chamber is made of an inert material designed to facilitate 
the deposition of the aerosol onto the cells without compro-
mising their viability.
A number of commercial in vitro exposure technolo-
gies exist which are (1) capable of consistently delivering 
and depositing aerosols at multiple dilutions, (2) compat-
ible with different types of aerosol generators, (3) capable 
of determining the deposited dose, (4) compatible with cell 
culture inserts used for ALI-grown cells, and (5) readily 
cleaned. However, some desirable traits are found absent in 
all current technologies, namely that high throughput is not 
available, and only short-duration (<6 h) single-exposure 
experiments have been demonstrated for each technology. 
An overview of aerosol generators and exposure chambers 
with regard to their applicability to the assessment of 
MWCNTs is discussed in the sections below.
Aerosol generation
Each aerosol generation method has advantages and disad-
vantages. For example, dry aerosol generation more closely 
mimics the realistic human exposure that would be of 
regulatory concern. For the dry exposure, the atmosphere 
around the cell system needs to be humidified to simulate 
physiological conditions. Wet aerosol generation, on the 
other hand, involves administration of NMs encased in liq-
uid droplets, which may induce agglomeration and intro-
duce liquid onto the cells, possibly altering the cellular 
outcome. However, one study has demonstrated that the 
increase in the volume of the liquid layer does not alter the 
biological effect of the aerosolized NM (Lenz et al. 2009). 
Although dry aerosol generation of MWCNTs is preferred 
over wet in order to link dosimetry considerations to bio-
logical outcomes (e.g., fibrosis), the wet generation meth-
ods can be used to develop the cell system to predict fibro-
sis and might provide the advantages of low cost, ease of 
use, and inter- and intra-laboratory transferability.
To maintain optimal conditions while the cells are inside 
the aerosol chamber for short exposure (minutes to 1 h), a 
thermostat-controlled incubation chamber (37 °C) should 
be used and the exposure system should be humidified to 
80–95 % relative humidity. For longer exposures, it is rec-
ommended to use HEPES-buffered cell culture media (con-
stant pH) or to supply 5–7 % carbon dioxide for media that 
are buffered by this gas.
All of the aerosol generation methods discussed during 
the workshop have been used to aerosolize CNTs; thus, the 
choice of the appropriate method largely depends on CNT 
concentration range and the aerosol particle size range 
desired. For humans, respirable particles (i.e., particles that 
enter the lower respiratory tract) have a mass median aero-
dynamic diameter (MMAD) of less than 5 µm while, for 
rats, respirable particles have a MMAD of less than 2.5 µm. 
The size of the aerosol particles (individual nanofibers, 
agglomerates, or aggregates) and the mass deposited on 
the cells (dose) could potentially lead to differential toxic-
ity outcomes. In addition to the ability to control and deter-
mine relevant dose metrics for the end points of interest, 
the price, ease of cleaning, ease of use, size of the genera-
tors, and interlaboratory transferability should be consid-
ered when evaluating equipment for such studies.
Exposure chamber design
Factors to consider when selecting an ALI exposure cham-
ber include reproducibility, ease of cleaning and use, cost, 
commercial availability, compatibility with test materials, 
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number and size of the wells in the chamber, configura-
tion, modularity, and flexibility to add online and off-line 
equipment. Many of the chambers share common features, 
such as their compatibility with commercially available 
cell culture inserts, a mechanism to regulate temperature 
during exposure, and their ability to be used with multiple 
aerosol generators and to expose cells cultured at the ALI 
to aerosolized MWCNTs. However, there are differences 
that make each system unique. For example, the available 
ALI exposure chambers vary in the flexibility of connec-
tions and peripherals. While modularity can allow for 
more sophisticated testing, it also adds a level of complex-
ity, thereby requiring more expertise and training for use 
relative to simpler systems. It is important to note that, for 
modular systems, small alterations to the connections and 
peripherals (such as a change in the length of the tubing 
used) can alter results.
Dosimetry
Accurate and appropriate administration and monitoring of 
NM deposition is critical, with aspects such as the relevant 
target scenarios for administered doses and cellular dose 
metrics to use, modes of NM deposition, and measurement 
of administered versus cellular dose to be included in con-
siderations. The administered dose range should include 
concentrations relevant to occupational exposures to CNTs, 
encompassing several deposited/cellular doses in order to 
obtain a dose–response curve. For carbon nanotubes and 
carbon nanofibers, the National Institute for Occupational 
Safety and Health (NIOSH) recommends that exposures be 
controlled to less than 1 μg/m3 of respirable elemental car-
bon as an 8-hr time-weighted average2 and that, until expo-
sure limits are established, to follow best practices to 
reduce exposures (e.g., engineering controls, personal pro-
tective equipment, and medical screening or surveillance) 
(NIOSH 2013). While this recommended exposure limit is 
helpful for regulatory purposes, it has not been adopted as a 
permissible exposure limit by the Occupational Safety and 
Health Administration and is based on limited data (NIOSH 
2013). Therefore, in addition to testing concentrations that 
can be related to the occupational exposures of CNT, a dose 
range that represents doses shown to cause fibrosis or indi-
cate pro-fibrotic potential in existing in vivo and in vitro 
studies should also be tested (see also dosimetry modeling 
below) (Li et al. 2013; Godwin et al. 2015).
2 Few occupational exposure limits exist specifically for nanomate-
rials. Certain nanoparticles may be more hazardous than larger par-
ticles of the same substance. Therefore, existing occupational expo-
sure limits for a substance may not provide adequate protection from 
nanoparticles of that substance.
There are challenges associated with the administration 
of a dose in a consistent and reproducible manner to cells 
cultured at the ALI. The gravitational settling of MWC-
NTs takes a long time due to their low density and mass, 
which may lead to issues keeping the cell layer moist at the 
ALI. However, most of the available exposure systems are 
capable of maintaining constant temperature and humidity 
for the duration of exposure. Regardless, the cell system 
should be monitored throughout the exposure using TEER 
measurements and histopathological analysis at different 
time intervals to evaluate epithelial cell barrier integrity. 
Deposition could be enhanced using electrostatic force, but 
there are significant concerns regarding the applicability of 
this method to realistic exposures.
Mass, surface area, and nanostructure number should be 
considered as dose metrics because all three are considered 
at the OECD level (OECD 2012b). In fact, deposition of 
MWCNTs can be measured as a function of mass [quartz 
crystal microbalance (QCM)], surface area, or particle 
count (electron microscopy grid). ALI systems that are 
compatible with a QCM sensor for monitoring deposited 
dose are preferred because they can measure deposition in 
the nanogram range. While this is simple for a dry aero-
sol, it is more difficult for a wet aerosol as discussed above. 
Additional measurement of MWCNTs on a count basis 
may enable hazard characterization on a fiber count basis 
analogous to asbestos.
Characterization of dose at multiple stages 
during NM life cycle
When developing an in vitro test system to gauge potential 
hazards related to respiratory toxicology, characterizing the 
aerosol delivery to cells is critical for accurate interpreta-
tion of the results. The dosimetry determinants that dictate 
aerodynamics and deposition mechanisms (such as den-
sity and the bivariate (length and width) size distribution), 
the amount of NMs that reach the cell surface (deposited 
dose), and the amount of NMs taken up by the cells (cel-
lular dose) are all critical parameters needed to interpret 
the observed biological responses (Oberdorster et al. 2005; 
Teeguarden et al. 2007). Additionally, NM life cycle trans-
formations, including agglomeration (either homoagglom-
eration or heteroagglomeration with other colloids), disso-
lution, and changes in surface properties (biodegradation 
and corona formation), should be well characterized during 
the course of the assay in an effort to take into account spe-
cific transformations that may occur, and to support dose 
translation across experimental systems (i.e., in non-animal 
vs. in vivo systems) as well as data integration for environ-
mental conditions for real-world applications. Figure 4 out-
lines considerations such as when to characterize the NM, 
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what parameters to monitor, and what techniques to use for 
characterization.
When NMs are purchased, information about the NM 
generation method, the date of manufacture, and how the 
material is stored and supplied should be obtained from 
the supplier and reported in publications. While not always 
achievable due to budget and resources, it is ideal to char-
acterize NMs (1) in their original dry form; (2) as aero-
solized particles; (3) as deposited on the cell surface; and 
(4) following cellular uptake at multiple post-exposure time 
points throughout the course of the study. For the purposes 
of the case study discussed during the workshop, character-
ization data on the pristine form of the Mitsui-7 MWCNTs 
has already been reported in the literature (Poland et al. 
2008; Taquahashi et al. 2013; Sargent et al. 2014). Addi-
tionally, characterization information for standard reference 
materials, such as the Nanocyl 7000, is available through 
the Joint Research Center (JRC 2014) and has also been 
reported in the literature (Vietti et al. 2013). It would be 
beneficial to coordinate additional efforts like the Minimal 
Information for Nanomaterial Characterization (MINChar) 
Initiative to develop a minimal list of recommended char-
acterization parameters for NM studies (Bouwmeester et al. 
2011).
Aerosolized NMs can be characterized by an aerody-
namic particle sizer (APS), scanning mobility particle sizer 
(SMPS) spectrometer, and micro-orifice uniform deposit 
impactor (MOUDI). It is crucial to characterize aerosolized 
NMs to determine the form that the cell systems are being 
exposed to in order to extrapolate from system to system 
(DeLoid et al. 2014). In other words, aerodynamic prop-
erties and aerosol behavior of MWCNTs in their singlet 
form may be very different from the “tumbleweed” form 
that occurs following NM aerosolization. While the den-
sity of the singlet form has traditionally been used for 
most materials, the density of “as-generated” structures is 
more important for MWCNTs. In the “tumbleweed” form, 
the aerodynamic diameter and the effective density of the 
MWCNTs are lower, which is why larger particles can be 
inhaled.
Deposited structures can be characterized qualitatively 
using microscopy (e.g., CytoViva®), and deposited mass 
quantitatively determined using a QCM. Particle count and 
size information can be determined using electron micros-
copy. The cellular internalization and possible localization 
of NMs can be examined qualitatively by TEM or quan-
titatively by inductively coupled plasma mass spectrom-
etry (ICP-MS), which measures the amount of trace metal 
impurities associated with the MWCNTs.
Ideally, characterization of the original NM should 
include analysis of properties, such as surface area [using 
the Brunauer, Emmett, and Teller (BET) method], dusti-
ness (according to DIN 55992-2), impurity profile/con-
tent, effective density (using gas pycnometry), rigidity 
(via imaging and field emission SEM), and bivariate dis-
tribution (BVD) (i.e., length and diameter) (Lehman et al. 
2011). The properties that should be characterized during 
NM exposure are agglomerate structure, (de)agglomeration 
potential (via the Tendel test), and surface charge (when 
NMs are in a relevant medium). The aforementioned char-
acteristics dictate the life cycle transformations that NMs 
undergo and therefore their potential ecological and biolog-
ical effects. For instance, the rigidity and length of MWC-
NTs impact the level of agglomeration, which in turn dic-
tates the localization and toxicological impact of nanotubes 
in the physiological system (Donaldson et al. 2010; Klein 
et al. 2012).
Dosimetry modeling to aid experimental design, 
evidence integration, and inferences
Dosimetry modeling is well established as a useful bridge 
to link exposure to internal dose and the resultant response. 
Calculation of the internal dose associated with expo-
sure improves the accuracy of risk assessment (Jarabek 
et al. 2005). Dosimetry models quantitatively describe the 
aerodynamics of inhaled aerosols, including inhalability 
and mechanisms of deposition (interception, impaction, 
sedimentation, and diffusion), in the respiratory tract to 
predict deposited dose. Dosimetry models also quantita-
tively describe clearance kinetics (including mechanisms 
of mucociliary clearance, translocation, and dissolution) 
to estimate the dose retained in respiratory tract tissues 
(retained dose is equal to inhalability plus deposition, 
•Agglomerate structure (1, 2, 3, 4)
•(De)agglomeration potential (2, 3, 4)
•Impurity profile / content  (1)
•Effective density (2)
•Bivariate length and diameter 
distribution (BVD) (1, 2, 3)
•Surface charge (1, 2)
•Surface area (1)
•Rigidity (1)
•Dustiness (1)
•Cellular uptake (4)
1. Pristine form
2. As aerosolized
3. Deposited dose
4. Post exposure
Characterization stages: Characterization should include 
analysis of:
* The numbers (1, 2, 3,4) correspond to the 
characterization stages 
Fig. 4  NMs characterization during the course of a study. Ideally, 
NMs will be characterized in their original dry form, as aerosolized, 
as deposited, and at multiple time points during the course of the 
study. The characterization conducted will depend on the stage of 
the NM [i.e., (1) pristine form; (2) as aerosolized; (3) deposited dose; 
and (4) post-exposure] and, in this figure, the numbers 1 through 4 in 
parentheses following each parameter correspond to the four stages of 
NMs listed
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minus clearance). The relative contribution of impaction, 
interception, sedimentation, and diffusion to deposition 
is dependent on the respiratory tract region and species-
specific parameters (Asgharian et al. 2014). Species-spe-
cific airway anatomy and physiology, such as ventilation 
rate and breathing mode (i.e., nasal, oronasal, or mouth), 
are critical determinants of particle and fiber aerodynam-
ics, and vary with age and exertion level or activity pattern 
(e.g., resting vs. exercise). Particle parameters including 
density and size distribution are also critical determinants 
of aerodynamics, and biopersistence determines physical 
dissolution rates involved in clearance kinetics. Addition-
ally, to properly describe fiber aerodynamics, the bivari-
ate distribution of length and diameter is required (Cheng 
1986; Moss et al. 1994; Vincent 2005).
Dosimetry models, such as the multi-path particle dosim-
etry (MPPD) model (available from Applied Research 
Associates (ARA), Inc.), have been used (1) as the basis of 
size-selective exposure sampling and the National Ambi-
ent Air Quality Standard (NAAQS) for particulate matter; 
(2) for interspecies extrapolation of particle exposures in 
various species; (3) to understand uncertainties when using 
exposure as the dose metric; and (4) to provide insights into 
human variability due to age, ventilation rate, or disease 
(Anjilvel and Asgharian 1995; RIVM 2002). ARA, Inc. has 
released a version of the MPPD model developed in col-
laboration with NIOSH that describes deposition and clear-
ance kinetics for NM to predict retained dose, and an US 
EPA collaboration is developing an extension of MPPD to 
model asbestos fibers. Furthermore, emphasis on the need 
to describe dosimetry of in vitro test systems for accurate 
in vitro to in vivo extrapolation (IVIVE) motivated the 
development of the in vitro sedimentation, diffusion, and 
dosimetry (ISDD) model to predict particles delivered in 
solution to submerged monolayer cells and to understand 
the kinetics of NMs in in vitro systems (Hinderliter et al. 
2010).
Incorporating principles of dosimetry and quantitatively 
addressing fiber kinetics with in silico models will increase 
the predictive power of the test system and its usefulness 
in risk assessment (Stöber 1972; Anjilvel and Asghar-
ian 1995; Sturm and Hofmann 2006; Sturm 2009, 2011; 
Sturm and Hofmann 2009). In silico modeling approaches 
can be combined with existing data to devise a dosim-
etry paradigm for the design and interpretation of in vitro 
studies. The application of such modeling as an approach 
to improve the experimental design of in vitro test sys-
tems was discussed at the workshop. The relevant human 
scenario for regulation should be defined (e.g., exposure 
concentration, duration, and population) to aid the experi-
mental design and frame the inference approach (Holsap-
ple et al. 2005; Jarabek et al. 2005; Teeguarden et al. 2007; 
Gangwal et al. 2011). Experimental parameters (including 
test species, exposure concentration, duration, and regi-
ment) from existing studies can be used to describe inter-
nal dose in the in vivo toxicity studies and support IVIVE. 
Potential dose metrics should be based on the likely mode 
of action for NMs (Jarabek et al. 2005; Oberdorster et al. 
2005; Teeguarden et al. 2007). Ideally, relevant parameters 
for the construction of the dose metrics are measured in 
the test systems. These parameters include deposited mass, 
number, and surface area of the NM in the alveolar region 
normalized to species-specific factors, such as alveolar sur-
face area (NIOSH 2013). Reference values can be used for 
species- and strain-specific parameters. Additionally, in 
silico models can use existing exposure data from animal 
tests to predict an equivalent exposure in vitro.
Conclusions and recommendations
This workshop discussed multiple components of a poten-
tial predictive in vitro test system for the determination of 
NM fibrogenic potential (Fig. 5). Work is currently under-
way to implement the workshop recommendations into the 
development of such a system. The goal was to develop an 
in vitro system that can contribute to addressing the regula-
tory safety testing requirements for inhaled NMs, thereby 
reducing time and cost of testing as well as decreasing the 
number of animals used for this purpose. The ultimate goal 
was to incorporate this in vitro fibrosis system into an inte-
grated approach for assessing the toxicity of inhaled NMs 
that can replace the subchronic rodent inhalation assay and 
protect human health.
The first step in implementing the workshop recom-
mendations for developing the in vitro pulmonary fibrosis 
system is the establishment of a robust, reproducible co-
culture system containing epithelial cells, macrophages, 
and fibroblasts. The second step is the implementation and 
Workshop
Recommend 
details on the 
design of in 
vitro system
Next step
Development 
of the system 
in one 
laboratory by 
testing 
MWCNTs and 
+ / - controls
Long-term goals
Additional testing, such as:
-Testing in additional labs
-Testing of other materials
-Development of other test 
methods
-Devise a testing strategy 
to reduce and replace the 
animal test
Fig. 5  Project plan. The ultimate goal was to devise a human-rele-
vant replacement for the 90-day rodent inhalation test for the hazard 
identification of inhaled NMs. This is a long-term project that will 
involve an integrated battery of multiple assays; however, the initial 
study discussed during this workshop will be a proof of concept to 
determine whether a tiered testing approach for the assessment of 
fibrogenic pathways can be developed to provide confidence in pri-
oritization decisions in the near-term. During the process outlined, it 
would be ideal to share study protocols and data with regulators in 
order to facilitate regulatory acceptance of the method
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optimization of an aerosol generation system along with 
characterization techniques that can generate a reliable 
aerosol of MWCNTs and the control particles. The third 
task involves selection of a target exposure scenario to aid 
experimental design and provide inference structure for 
IVIVE. The target scenario includes determining a range of 
concentrations that bracket concentrations used in historical 
in vivo tests and measuring needed parameters to describe 
dose metrics. The fibrotic response can be assessed follow-
ing exposure to a range of doses for positive and negative 
benchmark particles and then to the MWCNTs. Standard 
protocols, such as those for cell culture conditions (e.g., 
cell seeding densities, medium conditions, and different co-
cultures), aerosol generation (e.g., air flow and method of 
generation), and in silico modeling (list of NM properties 
and parameters linked to respiratory system) will need to 
be developed for all aspects of the system to facilitate inter-
laboratory transferability. In addition to testing co-cultures 
in an ALI system, simple mono- or co-culture submerged 
cell systems could be tested in parallel to see whether com-
parable results are obtained.
After the system has been optimized in one laboratory, 
testing should be expanded to additional laboratories to 
show interlaboratory reproducibility in order to establish 
whether such a system could be more widely used for pre-
dicting human health effects. The MWCNTs suggested 
(Mitsui-7s and Nanocyl 7000 MWCNTs) have already 
been tested in various in vitro and in vivo studies, including 
90-day rodent inhalation studies; thus, it will be possible to 
examine the validity of the in vitro test system using avail-
able data.
The study described would be a proof of concept to 
determine whether a tiered testing approach for the assess-
ment of (pro-)fibrogenic pathways can be developed to 
provide confidence in prioritizing decisions (Fig. 6). The 
full data set and protocols from the testing conducted to 
develop the ALI system could be made available to regula-
tory agencies for consideration. While the method is under-
going consideration for regulatory use, a near-term use 
of the system could be for manufacturers to apply it in a 
safety-by-design approach; for example, the in vitro testing 
system can be used in conjunction with predictive chem-
informatics and read-across approaches during the early 
stages of materials design and production to decide which 
NMs will be included in product development. Also in the 
near-term before the method may be generally accepted 
for regulatory use, companies may conduct the in vitro 
method alongside the required 90-day inhalation test using 
the same materials and share the results with regulators so 
that both the companies and regulators can assess the simi-
larities and differences in the prediction of NM fibrogenic 
potential of the same test material using the two (in vitro/in 
vivo) testing schemes.
Longer-term plans could include using the system to 
test other NMs and non-nanosubstances and to rank sub-
stances in the order of toxicity. Ultimately, the develop-
ment of OECD and US EPA test guidelines will be impor-
tant if the method is to be widely used in a regulatory 
context. To be incorporated into test guidelines, the system 
would need have demonstrated relevance and reliability 
to adverse lung effects considered in regulatory contexts 
(OECD 2005).
While most of the workshop discussions focused on 
an achievable first-generation in vitro test system, there 
was also discussion of the ways in which the test system 
could be expanded to further mimic the human situation. 
For example, rather than manually seeding cells, bioprint-
ing could more reproducibly assemble thin layers of cells 
(Horvath et al. 2015). Additionally, primary cells isolated 
from diseased patients could be used to mimic human dis-
ease states. Furthermore, fluidic models and “human-on-
a-chip” technologies could be used to allow for complex 
interactions between different tissue types. Examples of 
such models include one developed during the European 
Commission’s 7th Framework Programme-sponsored 
InLiveTox project (InLiveTox 2012), the lung-on-a-chip 
model developed at Harvard University’s Wyss Institute 
(Huh et al. 2010), the captive bubble surfactometer system 
(Schurch et al. 2014), and the moving membrane air–liquid 
interface (MALI) bioreactor system developed at the Uni-
versity of Pisa, Italy (Cei et al. 2014). Overall, a number of 
options exist to transform a static model to include fluidics 
and membrane mobility. The developed system could also 
be modified to examine end points other than fibrosis, such 
as COPD, emphysema, or asthma.
Evaluation of existing data
Grouping and read-across
In silico modeling
In vitro: submerged acellular, mono- and co-culture systems
In vitro: ALI co-culture systems
Short-term (5-day) rodent inhalation testing
Sub chronic (90-day) rodent inhalation testing
Fig. 6  Proposed tiered testing approach for the assessment of the 
inhalation toxicity of nanomaterials. As confidence grows in the non-
animal methods, the goal is to replace the high cost, slow, and techni-
cally difficult animal inhalation studies
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